Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Speedus (CE) Charts. Click Here for more Speedus (CE) Charts.](/p.php?pid=staticchart&s=NO%5ESPDE&p=8&t=15)
Zargis Conducts Physician Study to Show Potential Benefits to
Physicians, Insurance Companies and Patients
PRINCETON, N.J., June 30 /PRNewswire/ -- Zargis Medical Corp., a spin-off from
Siemens Corporate Research, and a majority-owned subsidiary of Speedus Corp.
(NASDAQ:SPDE), today announced that it conducted a study in participation with
Johns Hopkins University's School of Medicine to assess the impact of the
Zargis Acoustic Cardioscan(TM) (ZAC(TM)) system on referral decisions made by
primary care physicians regarding heart murmurs -- which are potential signs of
heart disease. In addition, the study was designed to assess ZAC's ability to
support physicians in the detection of murmurs.
This study was based on the analysis, by a group of primary care physicians, of
a series of heart sound recordings obtained from anonymous subjects who were
referred to Johns Hopkins Hospital for a cardiology consult. The results of the
study are expected to be available later this year.
About Zargis Medical Corp.
Zargis Medical Corp. develops advanced diagnostic decision support products and
services for primary care physicians, pediatricians, cardiologists and other
healthcare professionals. Zargis was formed in 2001 when Siemens Corporate
Research, a division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to
develop and market an advanced acoustic technology designed to detect heart
abnormalities identified through analysis of heart sounds.
About ZAC
Zargis has developed ZAC, the first and only FDA-authorized computer- assisted
medical device to support physicians in analyzing heart sounds for the
identification of suspected murmurs. The non-invasive device is easy to use,
portable, and takes just minutes to perform. ZAC implements voice-guided
protocol and a graphical user interface while maintaining an efficient
physician workflow. The system provides a summary of findings in terms that are
readily understood by physicians and offers an additional range of quantitative
auscultatory information that cannot be obtained through listening alone. As a
result, ZAC enhances auscultation -- a procedure that has been universally
employed through a stethoscope for nearly two hundred years.
About Speedus Corp.
Speedus Corp. is a holding company with controlling interests in Zargis Medical
Corp. and F&B Gudtfood Holdings, Inc. Speedus Corp. also owns broadband
intellectual property and controls licensed wireless frequencies.
For additional information about Zargis Medical, Speedus Corp. or the ZAC
product, contact Peter Hodge at 888.773.3669 (ext. 23) or , or visit the
following Web sites: http://www.zargis.com/ and http://www.speedus.com/.
Statements contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate identity and
focus, may be forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that could cause
actual results to differ materially from those expressed in any forward-
looking statements made by the Company, including, but not limited to, the
continuing development of the Company's sales, marketing and support efforts.
DATASOURCE: Zargis Medical Corp.
CONTACT: Peter Hodge, 1-888-773-3669, ext. 23, , for
Zargis Medical Corp.
Web site: http://www.zargis.com/
http://www.speedus.com/